Payment overview · 2025
General Payments
$301.91
17 reported records · 11 companies
Healthcare provider profile · identity verified
Eric Abary Comsti, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKEHURST, NJ · NPI 1598723827
Verified facts
What the public records show
CMS Open Payments records show Eric Abary Comsti, MD received $301.91 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.84 | 21.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.13 | 15.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.75 | 11.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.59 | 9.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.81 | 7.9% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $21.76 | 7.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.23 | 6.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.46 | 5.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.94 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.81 | 5.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.59 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $301.91 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.13 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 852 | 242 |
| Levothyroxine Sodium | Levothyroxine Sodium | 516 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 505 | 152 |
| Alprazolam | Alprazolam | 495 | 112 |
| Losartan Potassium | Losartan Potassium | 368 | 108 |
| Eliquis | Apixaban | 365 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 321 | 104 |
| Sertraline Hcl | Sertraline Hcl | 290 | 83 |
| Lisinopril | Lisinopril | 281 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 79 |
| Furosemide | Furosemide | 241 | 77 |
| Metformin Hcl | Metformin Hcl | 232 | 75 |
| Omeprazole | Omeprazole | 220 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 57 |
| Gabapentin | Gabapentin | 169 | 40 |
| Azithromycin | Azithromycin | 167 | 123 |
| Simvastatin | Simvastatin | 164 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 49 |
| Potassium Chloride | Potassium Chloride | 150 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 36 |
| Carvedilol | Carvedilol | 133 | 30 |
| Valsartan | Valsartan | 128 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 17 |
| Januvia | Sitagliptin Phosphate | 121 | 17 |
| Mirtazapine | Mirtazapine | 111 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 49 |
| Glimepiride | Glimepiride | 101 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 19 |
| Allopurinol | Allopurinol | 88 | 27 |
| Amoxicillin | Amoxicillin | 86 | 56 |
| Spironolactone | Spironolactone | 85 | 20 |
| Tramadol Hcl | Tramadol Hcl | 85 | 21 |
| Farxiga | Dapagliflozin Propanediol | 83 | 15 |
| Xarelto | Rivaroxaban | 83 | 18 |
| Donepezil Hcl | Donepezil Hcl | 81 | 19 |
| Synthroid | Levothyroxine Sodium | 79 | 21 |
| Temazepam | Temazepam | 79 | suppressed |
| Lorazepam | Lorazepam | 77 | 14 |
| Glipizide Er | Glipizide | 74 | 21 |
| Finasteride | Finasteride | 72 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 53 |
| Montelukast Sodium | Montelukast Sodium | 67 | 21 |
| Atenolol | Atenolol | 65 | 16 |
| Cefuroxime | Cefuroxime Axetil | 62 | 53 |
| Clonazepam | Clonazepam | 62 | 11 |
| Nifedipine Er | Nifedipine | 60 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 20 |
| Metformin Hcl Er | Metformin Hcl | 57 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 14 |
| Lovastatin | Lovastatin | 53 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 12 |
| Cephalexin | Cephalexin | 41 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Irbesartan | Irbesartan | 39 | 12 |
| Jardiance | Empagliflozin | 39 | 13 |
| Meclizine Hcl | Meclizine Hcl | 38 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 20 |
| Prednisone | Prednisone | 33 | 18 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 21 |
| Famotidine | Famotidine | 31 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 28 |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Ozempic | Semaglutide | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Anastrozole | Anastrozole | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 17 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Nyamyc | Nystatin | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Repaglinide | Repaglinide | 24 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 12 |
| Procrit | Epoetin Alfa | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $301.91 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Andembry, BREZTRI, FARXIGA, GEMTESA, JARDIANCE, KISUNLA, Kerendia, Korlym, Leqembi, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error